[Media Release] Focused Report: Clinician-Supported Emerging Treatment Options, Radiation Dermatitis
An Informative Review for Healthcare Providers
Quest Healthcare, A Division of Quest Products, LLC. (Quest Healthcare), a healthcare solutions company focused on delivering innovative healthcare products that improves patients’ overall quality of life, today released an informative review fortitled, “Current Prevention and Management of Radiation Dermatitis: A Focus on Pharmalogic and Emerging Treatments,” summarizing guideline recommendations for management and prevention of radiation dermatitis and providing research-driven insight on effective treatment options, including, the use of ALOCANE® Plus – a topical anesthetic & antimicrobial product produced by Quest Products, LLC. and distributed by Quest Healthcare.
The published report sponsored by Quest Healthcare reveals approximately 95% of cancer patients receiving radiation therapy will experience radiation dermatitis at some point during their treatment. Despite the incidence of radiation dermatitis, evidence supporting the use of pharmacologic interventions for prevention or treatment is insufficient. Currently, only topical therapies are recommended by experts for prevention and management.
“We feel this study uncovers the substantial advantages provided by the proactive use of ALOCANE® Plus on patients experiencing radiation dermatitis,” states Margaret Swantko, Director of Sales and Education for Quest Healthcare.
Among the recommended emerging treatments listed in this report is ALOCANE® Plus, an anesthetic & antimicrobial product predominately used to treat early stage wounds, pressure injuries and radiation dermatitis. Testimonials from clinicians support the use of ALOCANE® Plus as topical remedy to relieve pain and itching associated with radiotherapy. Additionally, one clinician reports patients following a treatment protocol with ALOCANE® plus saw resolution of radiation dermatitis within a month of initial use.
ALOCANE® Plus, a healthcare product of Quest Products, LLC, offers relief from pain, irritation, dryness and skin damage caused by a range of skin issues, including minor cuts, scrapes and ulcerations. ALOCANE® Plus contains 4% lidocaine, the highest levels allowed and approved by the FDA without a prescription, as well as antimicrobial Benzalkonium Chloride to help prevent infection and the anti-inflammatory, pain-relieving, and healing properties of the aloe plant.
“Quest Products, LLC and Quest Healthcare are proud of the innovative research and development of quality products, such as ALOCANE® Plus, which allows both companies to provide healthcare providers across the country the ability to enhance the quality of life of their patients,” adds Quest Products, LLC SVP of Business Development, Mark McGreevy.
Click here to download the special report sponsored by Quest Healthcare.
About Quest Healthcare, A Division of Quest Products, LLC
Quest Healthcare prides itself on distributing healthcare products that pursues integrity and humanity, and provides those facing life-altering illness or injury the opportunity to reclaim their lives. Widely known by healthcare professionals and consumers alike for its four main health care products, ALOCANE® Plus, Clinere™, ENEMEEZ® and OraCoat®, Quest Healthcare also provides an extensive network of information to assist healthcare providers in their pursuit to provide superior care for their patients. Providers and consumers can purchase Quest Healthcare products and samples via its website and over the counter at local and chain pharmacies throughout the United States.
# # #
CONTACT INFORMATION:
Mark McGreevy
SVP, Business Development
(262) 925 – 0987
mark.mcgreevy@puestproductsInc.com
Margaret Swantko
Director of Sales & Education
(602) 385 – 1120
